Business and corporate development; alliance and partnership management
Our collaboration and strategic development activities are guided by a structured operating model designed to ensure rigor, strategic alignment, and the creation of sustainable value.
Strong alliance management oversight supports the governance and evolution of partnerships, while established due-diligence processes ensure accurate and systematic evaluation of opportunities.
This approach reflects our commitment to informed decision-making, long-term relationships, and high-quality collaborations.
Respiratory diseases
Contact us for new projects under development (from early pre‑clinical phases up to registration phase) and marketed products in the respiratory area, particularly for the treatment of asthma, COPD, IPF, PAH, and non‑CF bronchiectasis.
- Asthma and COPD
- Interstitial lung disease (e.g. IPF)
- Pulmonary arterial hypertension (PAH)
- Non-CF Bronchiectasis
- Small molecules
- Biologics
- RNA therapeutics
- From early research to late-stage/commercial assets
Irene Pasquali
Head of Global Business Development Air
Parma, Italy
Jeremy Burger
Associate Director Global Business Development Air
Cary, USA
Reach out to the team: BDAir@chiesi.com
Rare diseases
Contact us for projects under development (from early pre‑clinical phases up to registration phase) and marketed products, with a global focus on the rare diseases area and with specific attention to Inborn Errors of Metabolism (primarily Lysosomal Storage Disorders), Immunodeficiencies, Hemoglobinopathies, Endocrinology/Cardio-Metabolic, Dermatology, Ophtha back of the eye indications.
- Inborn Errors of Metabolism: primarily Lysosomal Storage Disorders
- Rare Immunodeficiencies
- Rare hemoglobinopathies
- Rare endocrinology/cardio-metabolic
- Rare Dermatology
- Rare ophtha, back of the eye indications
- Small molecules
- Biologics
- RNA therapeutics
- Gene editing
- From early research to late-stage/commercial assets
Mario Maruzzi
VP, Head of Global Business Development Rare
Parma, Italy
Alberto Parisi
Associate Director Global Business Development Rare
Parma, Italy
Reach out to the team: BDRare@chiesi.com
Special care and Primary care
Contact us for new projects under development (from the initial preclinical phase through to registration phase) and marketed neonatal products with a global focus, as well as marketed or late‑stage assets (post‑PoC) in Hospital Acute & Critical Care and Solid Organ Transplant.
- Hospital acute & critical care
- Solid organ transplant
- Neonatal conditions including BPD/CLD, PH-secondary to BPD, PPHN, HIE, seizures, NEC, intestinal malabsorption and other conditions related to poor growth and nutritional support, sepsis
- Small molecules
- Biologics
- RNA therapeutics (neo only)
- Gene editing (neo only)
- Hospital acute & critical care and solid organ transplant: commercial assets or late-stage post-PoC
- Neonatal: from early research to late-stage/commercial assets
Corey Hansen
Head of Global Business Development Care
Cary, USA
Alessandra Schiavon
Manager Global Business Development Care
Parma, Italy
Reach out to the team: BDCare@chiesi.com
Corporate Development
Our Corporate Development team leads mergers and acquisitions in coordination with the Business Development teams, divestment and out‑licensing activities, regional and local deals, and other types of transactions outside the scope of Air, Care, and Rare.
Alberto Borlacco
Head of Corporate Development
Parma, Italy
Wondosen Bianchini
Associate Director Corporate Development
Parma, Italy
Andrea Biancarini
Manager Corporate Development
Parma, Italy
Reach out to the team: CorporateDevelopment@chiesi.com